nach oben

Erschienen in:

Open Access 01.12.2015 | Research article

BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer

verfasst von: F. Z. Francies, T. Wainstein, K. De Leeneer, A. Cairns, M. Murdoch, S. Nietz, H. Cubasch, B. Poppe, T. Van Maerken, B. Crombez, I. Coene, R. Kerr, J. P. Slabbert, A. Vral, A. Krause, A. Baeyens, K. B. M. Claes

Erschienen in: BMC Cancer | Ausgabe 1/2015

Abstract

Background

Current knowledge of the aetiology of hereditary breast cancer in the four main South African population groups (black, coloured, Indian and white) is limited. Risk assessments in the black, coloured and Indian population groups are challenging because of restricted information regarding the underlying genetic contributions to inherited breast cancer in these populations. We focused this study on premenopausal patients (diagnosed with breast cancer before the age of 50; n = 78) and triple negative breast cancer (TNBC) patients (n = 30) from the four South African ethnic groups. The aim of this study was to determine the frequency and spectrum of germline mutations in BRCA1, BRCA2 and PALB2 and to evaluate the presence of the CHEK2 c.1100delC allele in these patients.

Methods

In total, 108 South African breast cancer patients underwent mutation screening using a Next-Generation Sequencing (NGS) approach in combination with Multiplex Ligation-dependent Probe Amplification (MLPA) to detect large rearrangements in BRCA1 and BRCA2.

Results

In 13 (12 %) patients a deleterious mutation in BRCA1/2 was detected, three of which were novel mutations in black patients. None of the study participants was found to have an unequivocal pathogenic mutation in PALB2. Two (white) patients tested positive for the CHEK2 c.1100delC mutation, however, one of these also carried a deleterious BRCA2 mutation. Additionally, six variants of unknown clinical significance were identified (4 in BRCA2, 2 in PALB2), all in black patients. Within the group of TNBC patients, a higher mutation frequency was obtained (23.3 %; 7/30) than in the group of patients diagnosed before the age of 50 (7.7 %; 6/78).

Conclusion

This study highlights the importance of evaluating germline mutations in major breast cancer genes in all of the South African population groups. This NGS study shows that mutation analysis is warranted in South African patients with triple negative and/or in premenopausal breast cancer.

Additional file 1: Table S1. Overview of grading and staging of breast cancer on diagnosis (DOC 30 kb)

Additional file 2: Table S2. Overview of sequencing coverage per run (DOC 29 kb)

Electronic supplementary material

The online version of this article (doi:10.1186/s12885-015-1913-6) contains supplementary material, which is available to authorized users.

F. Z. Francies, T. Wainstein, A. Baeyens and K. B. M. Claes contributed equally to this work.

Competing interests

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Authors’ contributions

FZF, TW carried out the molecular work, analysed data and helped draft the manuscript. KDL, BC, IC carried out the molecular work and analysis of data. AC, MM, SN, HC, BP, TVM provided samples for this study. RK, JPS, AV, AK revising the manuscript. AB, KBMC design of the study and drafting the manuscript. All authors have read and approved the manuscript.

MAF

Minor allele frequency

MLPA

Multiplex ligation-dependent probe amplification

NGS

Next-generation sequencing

Premenopausal

Triple negative

TNBC

Triple negative breast cancer

VUS

Variants of unknown significance

Background

Breast cancer is the most common cancer amongst South African women with a lifetime risk of 1 in 32 [1]. South Africa is a country consisting of citizens from diverse ethnic groups. These include: black/African (79.8 %), white/Caucasian (8.7 %), mixed ancestry/coloured (9.0 %) and Indian/Asian (2.5 %) (Statistics South Africa, 2013) [2]. According to the most recent report from the National Cancer Registry of South Africa, the lifetime risk of developing breast cancer differs according to ethnicity. The lifetime risk is 1/53 in black women, 1/15 in white women, 1/21 in coloured women and 1/20 in Indian women (National Cancer registry, NHLS, 2006) [1].

Breast cancer has a strong heritable component, with approximately 15–20 % of cases exhibiting a family history of the disease [3, 4]. Mutations in genes such as BRCA1 and BRCA2 lead to autosomal dominant inherited cancer susceptibility and confer a high lifetime risk of breast cancer, as well as ovarian and other cancers. Recently it was suggested that the risk to develop breast cancer for PALB2 mutation carriers is as high as the risk borne by BRCA2 mutation carriers [5]. Identification of mutations in these genes through clinical genetic testing enables patients to undergo screening and prevention strategies, some of which provide reduced morbidity. In addition, the c.1100delC mutation in CHEK2 has been identified as a susceptibility allele with incomplete penetrance and is associated with moderate lifetime risks of breast cancer. Data on the prevalence and spectrum of mutations in these genes are widely available for individuals of European descent. However, data for cohorts with African ancestry are scarce [6].

A few South African studies on mutations in BRCA1, BRCA2 and PALB2 are available [7‐10].Three South African population groups exist in which the presence of BRCA1/2 founder mutations occur; these are the Ashkenazi Jewish population [11], the Afrikaans population [7] and the black Xhosa population [10]. Other family-specific mutations have also been identified, as is typical of populations elsewhere. Table 1 shows data from studies done in South Africa to date. These studies have been performed mostly in white breast cancer patient cohorts. Furthermore, African populations are known to exhibit greater genomic diversity when compared to white populations, and genetic findings in one population cannot necessarily be extrapolated to another [12]. Consequently, there is a need to establish the aetiology of inherited breast cancer in this population. The epidemiology of breast cancer in South African black populations exhibits a number of unique trends when compared to other population groups worldwide. The difference in underlying genetic architecture, family structure, limited financial and human resources, limited community knowledge of breast cancer, limited information on family history and historical difficulty accessing health care, makes it more complex to perform risk assessments in these populations [13]. Overall, the cancer incidence in sub-Saharan Africa is lower as compared to developed countries but there is evidence to suggest changes in the disease burden as the impact of communicable diseases is mitigated [14]. South African women tend to be diagnosed with breast cancer at younger ages [15‐17]. However, the diagnosis only occurs at advanced stage due to the lack of awareness, access to diagnostic centres available and limited screening. Hence, the inclusion criterion for a “young” breast cancer or premenopausal (PM) breast cancer patient was set at 50 years (See Additional file 1: Table S1). While this could be due to a younger population structure, it is possible that these younger women carry unique mutations in certain genes. Breast cancer in young women is correlated with aggressive tumour progression, lack of expression of receptors and poor prognosis [18]. Furthermore, it is often attributed to a genetic predisposition with germline mutations in the BRCA1/2 genes [19‐22]. Younger women of African descent are known to be in the high-risk group with decreased survival rates [23].

Table 1

Literature overview on BRCA1 and BRCA2 mutations detected in a South African population

Study (Reference)	Ethnic group	Gene	Mutation detected	Patients/families tested	Frequency (%)	Detection method
Yawitch & Van Rensburg 2000 [51]	Black	BRCA1	N/A	0/206	0	PTT and SSCP/HA; limited to regions with Afrikaner founder mutations
Reeves et al., 2004 [7]	White/Ashkenazi Jewish	BRCA1	c.68_69delAG	4/18	4.4	PTT and SSCP/HA
	White	BRCA1	c.329dupA	1/18	1.1
	White	BRCA1	c.1008dupA	1/18	1.1
	White	BRCA1	c.1352C > A; p.S451*	1/18	1.1
	White/Afrikaner	BRCA1	c.1374delC	2/18	2.2
	White/Afrikaner	BRCA1	c.2641G > T; p.E881*	5/18	5.6
	Indian	BRCA1	c.4957insC	1/18	1.1
	White/Ashkenazi Jewish	BRCA1	c.5266dupC	3/18	3.3
Schlebusch et al., 2010 [52]	White/Afrikaner, Ashkenazi Jewish, Black, Indian	BRCA1	N/A	26/129	20.2	PTT and SSCP/HA and MLPA
		BRCA2	N/A	43/129	33.3
Sluiter et al., 2011 [9]	White/Afrikaner	BRCA1 + BRCA2	N/A	0/36		MLPA
	White/Ashkenazi Jewish	BRCA1	Ex23-24del	1/30	3.3
		BRCA2	N/A	0/30
Van der Merwe et al., 2012 [10]	Coloured	BRCA1	c. 1504_1508delTTAAA	1/105	1.0	PTT and SSCP/HA
		BRCA1	c. 2641G > T;p. E881*	1/105	1.0
		BRCA2	c. 2826_2829delAATT	1/105	1.0
		BRCA2	c. 5771_5774delTTCA	4/105	3.8
		BRCA2	c. 6448dupTA	1/105	1.0
		BRCA2	c. 7934delG	1/105	1.0
	Black	BRCA2	c. 5771_5774delTTCA	4/16	25.0
Schoeman et al., 2013 [13]	White, Mixed Ancestry, Black	BRCA1	c. 2641G > T; p. E881*	7/302	2.3	SSCP/HA
		BRCA1	c. 68_69delAG	2/302	0.7
		BRCA1	c. 1374delC	2/302	0.7
		BRCA1	c. 5266dupC	1/302	0.3
		BRCA2	c. 7934delG	17/302	5.6
		BRCA2	c. 5771_5774delTTCA	7/302	2.3
		BRCA1	N/A	4/302	1.3	PTT
		BRCA2	N/A	5/302	1.7
		BRCA1	N/A	2/302	0.7	Sequencing
		BRCA2	N/A	2/302	0.7	Sequencing
		BRCA1	N/A	18/302	6.0

PTT protein truncation test, SSCP/HA PCR-single strand conformation polymorphism/heteroduplex analysis, N/A mutations were not described; * indicates the presence of a premature stop codon (cfr. nomenclature HGVS (Human Genome Variation Society))

Another factor that is generally considered as an indicator of genetic susceptibility to breast cancer is the so-called “triple negative” histological phenotype. Approximately 15 % of breast cancers lack the expression of estrogen receptors, progesterone receptors and HER2/NEU receptors and are known as triple negative breast cancer (TNBC) [24]. This type of breast cancer is associated with an aggressive disease progression, higher histological grade, poor prognosis, high rate of recurrence and decreased survival rates. The frequent occurrence of TNBC is strongly correlated with younger patients of African descent and increased incidence has been noted among black South African breast cancer patients [16, 17, 25]. The strong association between TNBC and mutations in the BRCA1 gene, seen in European and American populations [26, 27], has not been investigated in a South African cohort.

This study aimed to evaluate the contribution of germline BRCA1, BRCA2 and PALB2 mutations and the CHEK2 c.1100delC allele to breast cancer in a high-risk South African cohort. Individuals included in the study were of different ethnicities (with a majority from the understudied black population) and had been diagnosed with premenopausal breast cancer (less than 50 years) or exhibited the “triple negative” histological phenotype. We chose to analyse BRCA1, BRCA2 and PALB2 as associated risks are well established and clinically relevant. In addition, the prevalence of CHEK2 c.1100delC was evaluated in this cohort and compared with the prevalence in individuals of European ancestry. We applied a cost efficient next generation sequencing (NGS) approach for analysis of the complete coding regions of BRCA1, BRCA2 and PALB2 [28]. Furthermore, large rearrangements have been reported in both BRCA1 and BRCA2 in several populations which may be missed by sequencing. We therefore complemented the sequencing approach with multiplex ligation-dependent probe amplification (MLPA), for these two genes.

Methods

Patients

EDTA blood samples of 108 breast cancer patients were collected from breast clinics in two state hospitals and a private hospital in Johannesburg - Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani Baragwanath Academic Hospital and Wits Donald Gordon Medical Centre respectively. Patients were selected if their tumour was triple-negative (TN), and/or their breast cancer diagnosis was premenopausal. All patients were categorized as black, white, Indian or coloured based on patients’ self-reported data from questionnaires. The cohort consisted of 85 black patients (78.7 %), 16 white patients (14.8 %), 5 Indians (4.6 %) and 2 coloureds (1.9 %). Table 2 presents the overview of the distribution of ethnicity in the cohort. All patients signed informed consent. Pathology data were obtained from the hospital files. Genetic counselling was offered to the patients, prior to obtaining their consent.

Table 2

Overview of distribution of ethnicity in our South African cohort

		Black (%)	White (%)	Indian (%)	Coloured (%)
Dx < 50 n = 92	TNBC	7 (7.6)	4 (4.3)	2 (2.2)	1 (1.1)
Dx < 50 n = 92	Not TNBC	70 (76.1)	5 (5.4)	2 (2.2)	1 (1.1)
Dx > 50 n = 16	TNBC	8 (50.0)	7 (43.8)	1 (6.3)	0
Total n = 108		85 (78.7)	16 (14.8)	5 (4.6)	2 (1.9)

Dx: Age at diagnosis

The study was approved by the Human Research Ethics Committee (Medical), University of the Witwatersrand (No. M091023; M110922; M130450).

DNA extraction

Genomic DNA was extracted from 4 - 6 ml of peripheral blood using a modified version of the standard salting out method [29].

Target enrichment, library preparation and sequencing

BRCA1, BRCA2 and PALB2 analysis was successfully conducted on 108 samples using Illumina’s Miseq desktop sequencer. Target enrichment was achieved by high throughput PCR. Primers were designed for the complete coding region including splice site regions of BRCA1 (31 amplicons), BRCA2 (42 amplicons) and PALB2 (19 amplicons) using Primer XL (www.pxlence.com). PCR conditions according to the protocol described by De Leeneer et al. were utilised [28].

Library preparation was performed using a modified version of the Nextera XT (Illumina) protocol. Sequencing was conducted on the MiSeq v2 instrument (Illumina Inc.) according to manufacturer’s instructions. The approach is described in detail by De Leeneer et al. [28].

Sanger sequencing

All genetic variants and pathogenic mutations identified via NGS were confirmed with Sanger sequencing. For confirmation by Sanger sequencing, an independent PCR amplification step was performed. In addition, the presence of all deleterious mutations was confirmed on an independently extracted DNA sample. All fragments with a coverage of <28× were also analysed by Sanger sequencing. For an overview of the number of amplicons that required Sanger sequencing, refer to Additional file 2: Table S2.

Nucleotide positions and protein translation correspond to reference sequence and Genbank account number NM_007294.3; NP_009225.1 for BRCA1, NM_000059.3; NP_000050.2 for BRCA2, NM_024675.3; NP_078951.2 for PALB2 and NM_007194.3 for CHEK2 c.1100delC. Nucleotide numbering uses the A of the ATG translation initiation start site as nucleotide 1.

MLPA

Large genomic rearrangements and/or gene dosage alterations in both the BRCA1 and BRCA2 genes were screened for in 108 patient samples using MLPA. BRCA1 MLPA analysis was performed using the SALSA MLPA P002 probemix (version C2-1113) (MRC-Holland) and BRCA2/CHEK2 MLPA using the SALSA MLPA P045 probemix (version B3-1113) (MRC-Holland). MLPA setup was performed according to the manufacturer’s protocol. Fragment detection and sizing was conducted using capillary gel electrophoresis on the ABI 3730XL genetic analyser (Applied Biosciences). All fragments positive for the CHEK2 mutation (c.1100delC) in the MLPA analysis were confirmed with Sanger sequencing.

The screening was performed in a research setting. We used the infrastructure and the protocols supplied by a molecular diagnostic laboratory with an ISO15189 accreditation.

Data analysis

Mapping of sequencing data was performed with CLC bio Genomics Workbench v6 software (CLC bio Inc.). Various in-house scripts were used for sequence analysis [28]. The Sanger sequencing data were analysed using SeqPilot v4.1.2 build 512 and SeqSpace v2.5.0. MLPA data were analysed using Coffalyser (MRC-Holland).

Variants of unknown significance (VUS) were evaluated using in silico mutation interpretation software – Alamut. We used the computational algorithms of SIFT, AlignGVGD, Polyphen and Mutation Taster for missense varaints and the splice site prediction programs SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer and Human Splicing Finder for intronic, silent and missense variants. Based on these predictions and in combination with a study of the literature and published minor allele frequencies, variants were classified in five classes. Unfortunately, due to limited availability of data, Bayesian likelihood analyses could not be performed to calculate the degree of likelihood of pathogenicity. Therefore, we applied the following rules:

Variants with a MAF (minor allele frequency) of > 0.01 were classified as class 1 (data not shown)
Variants were classified as class 2 if all prediction programs provided neutral scores (data not shown)
Variants with two or more programs with deleterious predictions were allocated to class 3 (Table 5)

All truncating and unequivocal splice site variants were considered as deleterious, in addition to missense variants in the RING domain of BRCA1 (class 4–5) (Table 3)

Table 3

BRCA1, BRCA2 and CHEK2 germline pathogenic mutations identified in triple negative and premenopausal breast cancer patients using NGS and MLPA

Patient no.	Ethnicity	Category	Gene	Exon	Nucleotide change	Amino acid change	Mutation effect	Reference
1	White	TNBC/PM	BRCA1	4	c.181 T > G	p.Cys61Gly	Missense	[53]
2	Black	TNBC/PM	BRCA1	4	c.212G > A	p.Arg71Lys	Missense	[54]
3	Indian	TNBC/PM	BRCA1	10	c.3593 T > A	p.Leu1198*	Nonsense	[55]
4	Black	PM	BRCA1	10	c.1155G > A	p.Trp385*	Nonsense	Novel
5	Black	PM	BRCA1	10	c.1953_1954insA	p.Lys652fs	Frameshift	Novel
6	White	TNBC	BRCA1 ^a	1–2	-	-	Deletion	[30]
7	Black	PM	BRCA2	7	c.582G > A	p.Trp194*	Nonsense	Novel
8	Black	TNBC	BRCA2	11	c.5771_5774delTTCA	p.Ile1924fs	Frameshift	[10]
9	White	PM	BRCA2	11	c.5213_5216delCTTA	p.Thr1738fs	Frameshift	[56]
9	White	PM	CHEK2 ^a	11	c.1100delC	p.Thr367fs	Frameshift	[39]
10	White	TNBC	BRCA2	17	c.7934delG	p.Arg2645fs	Frameshift	[10]
11	White	PM	BRCA2	17	c.7934delG	p.Arg2645fs	Frameshift	[10]
12	Indian	TNBC/PM	BRCA2	21	c.8754 + 1G > A	Non-coding	Splice site	[57]
13	Black	PM	BRCA2	23	c.9097_9098insA	p.Thr3033fs	Frameshift	[53]
14	White	PM	CHEK2 ^a	11	c.1100delC	p.Thr367fs	Frameshift	[39]

PM Premenopausal

^aMLPA results

^*indicates the presence of a premature stop codon (cfr. nomenclature HGVS (Human Genome Variation Society))

Statistical analysis

Mutation frequency was calculated with 95 % confidence intervals. The Fisher’s exact test was used to compare mutation frequencies in the different groups of patients. Statistical analysis was performed with Graphpad Prism software.

Results

In the total study population (n = 108), 15 heterozygous pathogenic mutations in 14 patients were identified (12.9 %; 95 % CI = 7.3–20.8 %): six in BRCA1, seven in BRCA2; two patients were found to carry CHEK2 c.1100delC of which one patient also harboured a deleterious BRCA2 mutation. All mutations were identified by sequencing on Miseq, except a large deletion in BRCA1 and the CHEK2 c.1100delC mutation which were detected by MLPA. No unequivocal deleterious mutations were identified in the PALB2 gene (Table 3).

The distribution of BRCA1/2 mutations among the different subgroups (TNBC and/or PM) and based on ethnicity is presented in Table 4. A significantly higher mutation detection ratio was obtained within the group of TNBC patients (7/30; 23.3 %; 95 % CI = 9.9–42.3 %) compared to the premenopausal breast cancer group without TNBC (6/78; 7.7 %; 95 % CI = 2.9–16.0 %) (p = 0.0432). Not surprisingly, the highest mutation detection ratio was obtained within the subgroup of TNBC patients diagnosed before the age of 50 (5/14; 35.7 %; 95 % CI = 12.7–64.9 %).

Table 4

BRCA1 and BRCA2 germline pathogenic mutations identified using NGS and MLPA in a South African cohort divided according to premenopausal diagnosis, triple negative status and ethnicity

Total n = 108	Dx < 50 n = 92 (85.2 %)				Dx > 50 n = 16 (14.8 %)		Total no. of mutations per ethnic group
Total n = 108	TNBC n = 14 (13.0 %)		Not TNBC n = 78 (72.2 %)		TNBC		Total no. of mutations per ethnic group
Black n = 85 (78.7 %)	n = 7		n = 70		n = 8		6 (7.1 %)
Mutations	BRCA1	BRCA2	BRCA1	BRCA2	BRCA1	BRCA2
	c.212G > A	-	c.1155G > A	c.582G > A	-	c.5771_5774delTTCA
	-	-	c.1953_1954insA	c.9097_9098insA	-	-
White n = 16 (14.8 %)	n = 4		n = 5		n = 7		5 (31.3 %)
Mutations	BRCA1	BRCA2	BRCA1	BRCA2	BRCA1	BRCA2
	c.181 T > G	c.7934delG	-	c.7934delG	Exon 1a-2 del	-
	-	-	-	c.5213_5216delCTTA	-	-
Indian n = 5 (4.6 %)	n = 2		n = 2		n = 1		2 (40.0 %)
Mutations	BRCA1	BRCA2	BRCA1	BRCA2	BRCA1	BRCA2
	c.3593 T > A	c.8754 + 1G > A	-	-	-	-
Coloured n = 2 (1.9 %)	n = 1		n = 1		0		0
Mutations	-		-		-		0
Total mutations per subgroup	5 (35.7 %)		6 (7.7 %)		2 (12.5 %)

The BRCA2 c.7934delG Afrikaner founder mutation was identified in 2 (white) patients, one with TNBC and one diagnosed with premenopausal breast cancer. In the black patient population, two previously unreported mutations were identified in BRCA1 (c.1155G > A and c.1953_1954insA) and one in BRCA2 (c.582G > A) (see Table 3). Six (6/85; 7.1 %; 95 % CI = 2.6–14.7 %) pathogenic BRCA1/2 mutations were observed in the black population group and five (5/16; 31.3 %; 95 % CI = 11.0–58.7 %) in the white population group. Two mutations were identified in the Indian group (2/5; 40 %; 95 % CI = 5.3–85.3 %) and no mutations were identified either in BRCA1 or BRCA2 in the two coloured individuals studied.

To detect large genomic rearrangements in BRCA1 and BRCA2, 108 samples were analysed using MLPA. A white TNBC patient was found to be heterozygous for a BRCA1 exon 1a-2 deletion. Several deletions including these exons but with different breakpoints have previously been described (for an overview of deletions affecting these exons: [30]). As the number of large rearrangements reported in PALB2 is extremely small [31], MLPA for PALB2 was not conducted in this cohort.

The CHEK2 mutation (c.1100delC) was observed in 2/108 (1.9 %) patients. Both of these patients were white, premenopausal patients. One of these patients was also positive for a deleterious BRCA2 mutation.

In addition to pathogenic mutations, several VUS were identified: 1 in BRCA1, 3 in BRCA2 and 2 in PALB2. In Table 5 we provide an overview of the variants which were classified as class 3 based on in silico prediction programs. Three of the four in silico prediction programs used classified the BRCA2 variant c.9875C > T and c.7712A > G as “probably damaging”. The BRCA2 variant c.9875C > T was identified in two black patients. Two of the four prediction programs consulted classified the PALB2 variants c.118A > G and c.2845 T > C as “probably damaging”.

Table 5

In silico predictions obtained for variants of unknown significance in the South African cohort

					In silico prediction programs
Ethnicity	Variant	Gene	Amino acid change	Occurrence	Classification	Align GVGD^a	SIFT	Mutation Taster	PolyPhen	Refs
Black	c.1843_1845delTCT	BRCA1	p.Ser615del	1	3	-	-	-	-	[58‐60]
Black	c.4798_4800delAAT	BRCA2	p.Asn1600del	1	3	-	-	-	-	[61]
Black	c.7712A > G	BRCA2	p.Glu2571Gly	1	3	C0	Deleterious	Disease causing	Probably damaging	[62]
Black	c.9875C > T	BRCA2	p.Pro3292Leu	2	3	C0	Affect protein function	Disease causing	Probably damaging	[63]
Black	c.118A > G	PALB2	p.Arg40Gly	1	3	C0	Affect protein function	Polymorphism	Probably damaging	Novel
Black	c.2845 T > C	PALB2	p.Cys949Arg	1	3	C0	Affect protein function	Disease causing	Probably damaging	Novel

^aSpectrum of prediction classes (C0, C15, C25, C35, C45, C55, C65) with C0 less likely to be deleterious and C65 most likely

Discussion

The current study is the first study performing mutation analyses in BRCA1, BRCA2 and PALB2 and determining the frequency of CHEK2 c.1100delC in triple negative and/or premenopausal breast cancer patients in South Africa through both next generation sequencing and large rearrangement testing. In total we detected 13 BRCA1/2 mutations in our study cohort of 108 patients (12 %; 95 % CI = 6.6–19.7 %), thus reinforcing the important contribution of germline BRCA1 and BRCA2 mutations to inherited breast cancer in this mixed South Africa cohort. Two patients harboured a CHEK2 c.1100delC mutation, one of them in combination with a deleterious BRCA2 mutation. Previous studies done on South African breast cancer populations reported BRCA1/2 mutation frequenciess of 1 to 25 % [7‐10] (for an overview: see Table 1). The prevalence of mutations in BRCA1/2 genes in these South African studies varies by inclusion criteria, ethnicity and mutation screening techniques used. None of these studies looked specifically at TNBC or premenopausal patients.

The mutation frequency was higher in the subgroup of TNBC than in the premenopausal breast cancer patients: 23.3 % (7/30) of TNBC patients harbour a pathogenic mutation in either BRCA1 or BRCA2, compared to 12.0 % (11/92) of all premenopausal breast cancer patients.

Various studies have shown the frequency of BRCA1 mutations to be higher than BRCA2 in patients exhibiting the triple negative phenotype [27, 32, 33]. In our study 13.3 % (4/30) of TNBC patients had a pathogenic mutation in BRCA1 compared to 10 % (3/30) in BRCA2.

In our premenopausal cohort, the prevalence of BRCA1 mutations were similar (5/92; 5.4 %) to BRCA2 mutations (6/92; 6.5 %). BRCA2 mutations are in general less frequent than BRCA1 in younger white women with breast cancer [19]. A relatively high number of BRCA2 mutations compared to BRCA1 has been reported in other studies of young black populations [34‐36] and is contradictory to the scenario in Western populations. This could be due to the unique genetic background of African patients.

In the black population, the overall frequency of mutations identified was 7.1 % as compared to 31.3 % in the white population. Due to the presence of the BRCA2 c.7934delG Afrikaner founder mutation, BRCA2 is the most important contributor in the white population in our study cohort, while BRCA1 and BRCA2 mutations were observed in equal numbers in the black patients studied. We identified neither the Ashkenazi Jewish nor the Xhosa mutations in our study groups. Our patient cohort was recruited in the region of Johannesburg and is characterized by diverse population structure/ethnic backgrounds. Therefore we did not anticipate finding a large number of founder mutations.

The CHEK2 c.1100delC allele contributes to a moderate increased breast cancer risk. The frequency is estimated to be only 1 % in familial breast cancer and 0.5 % in early onset breast cancer [37, 38]. In the Dutch population the prevalence in the general population is 1.1 %, 2.5 % in unselected breast cancer cases, and up to 4.9 % in familial breast cancer cases [39]. Within our South African cohort we identified this allele in two white patients (2/16 = 12.5 %), but in none of the patients from other ethnicities (0/92). White Afrikaner South Africans mainly descend from Dutch immigrants which could explain the higher percentage of CHEK2 c.1100delC in this cohort.

Previous studies that aimed to clarify the prevalence of BRCA1/2 mutations in black populations from other parts of Africa and African Americans have indicated similar rates [6, 22, 27, 36, 40]; although it is difficult to compare them since eligibility criteria for study participation varies extensively. Churpek et al. [40] reported a pick-up rate of 26 % (47/180) for pathogenic mutations in a group of black patients with early onset disease (age of diagnosis <45) and 25 % pick-up rate (26/103) for pathogenic mutations in triple negative black patients. Here we report BRCA1/2 mutation frequency of 14 % (1/7) in the premenopausal triple negative black subgroup. Our overall mutation detection rate of BRCA1/2 mutations in the black premenopausal breast cancer patients was 6.5 % (5/77). This is similar to the mutation rate reported in a study by Pal et al. [22] in young black African American breast cancer patients (9 %; 13/144). Although the prevalences are similar among the studies on West African, African American breast cancers and our study, we identified 3 novel mutations in the South African black patients. Furthermore, historical evidence has shown that African Americans descend from West African ancestry and so it is not surprising that there are some differences between these two and the South African black population, who have some distinct genetic differences at the population level [12, 41].

Large genomic rearrangements in BRCA, detected with MLPA, were only observed in 0.9 % (1/108) of our cohort. No large rearrangements were identified in the black South African breast cancer patients. Generally, low frequencies for large rearrangements have been reported in black patients, e.g. Pal et al., [22], detected 2 rearrangements in 144 young African-American women with breast cancer (1.4 %), both of which were in BRCA1. Zhang et al., [42] reported one BRCA1 exon deletion (0.3 %) in a cohort of 352 Nigerian breast cancer patients. In another South African study on 52 unrelated families of European ancestry, only 1 large deletion was detected in BRCA1 [9]. The lack of detection in BRCA2 led the authors to suggest that large rearrangements in BRCA2 might not play a role in inherited breast cancer in South African patients [9]. However, to draw final conclusions on the presence of large rearrangements in both white and black South African breast cancer patients, a larger patient population should be extensively studied.

Gene sequencing techniques also resulted in the identification of several VUS. Based on in silico predictions, we assigned a class (class 1– 3) to each VUS for clinical interpretation [43]. VUS with a probability of increased pathogenicity are assigned a higher class. A number of studies have presented models and performed functional assays for the classification of VUS in BRCA1/2 [43‐46]. We detected six VUS in the 85 black patients of our cohort and none in the 16 white patients. Also other studies suggested that the frequency of VUS is higher in patients of African descent, for instance Nanda et al. [47].

A previous study conducted in a South African cohort revealed a pathogenic PALB2 mutation in 2 % of early onset white breast cancer patients [8]. Our cohort consisted of a small number of white patients and no unequivocal deleterious mutations in PALB2 were identified. However two missense variants with suggestive in silico predictions were identified (Table 5) that warrant further functional analyses. Until recently, the pathogenic effect of PALB2 missense variants has not been firmly proven. For some missense variants in the WD40 domain (from amino acids 853–1186) [48] altered patterns of direct binding to the RAD51C, RAD51 and BRCA2 h proteins in biochemical assays have been shown [49]. We identified a missense variant in the WD40 domain (c.2845 T > C; p.Cys949Arg). In order to elucidate the pathogenicity of missense variants in PALB2, additional (functional, segregation) analyses are required.

We focused on identifying mutations in BRCA1, BRCA2 and PALB2 and the CHEK2 c.1100delC mutation, as the risks for the development of breast and associated cancers with these genes have been determined by analysing large study populations. The search for the remaining genetic contribution towards breast and ovarian cancer has been carried out extensively, with numerous other genes being identified. However, at this time, the contribution and associated risks of mutations in most of these genes is not yet well established. As the prevalence of mutations in each of these genes is much lower than germline BRCA1/2 mutations in the large cohorts (white American) of patients investigated up until now [50], international collaborations in populations of different ethnicities will be required to gain insight into the exact risks associated with mutations in these genes.

Conclusion

This study is the first to evaluate the use of NGS technology as a diagnostic testing platform for inherited breast cancer in a South African cohort. The results presented herein are particularly relevant for inherited cancer testing in the black population of South Africa, a previously under-researched group. The NGS approach applied [28] is a cost and time effective approach; it shows great promise for BRCA1/2 screening in developing countries like South Africa. The advent of NGS allows the costs of mutation analysis to fall dramatically, which should allow testing to become more widely available, especially in countries with limited healthcare resources, like South Africa. This will create opportunities to improve patient treatment and challenges for breast cancer multidisciplinary teams. The finding of a germline deleterious mutation could alter treatment decisions; for instance, women with germline mutations might opt for more radical surgery or may consider prophylactic surgery to the contralateral breast or ovaries.

Our results have highlighted the contribution of BRCA1/2 germline mutations in South African breast cancer patients with triple negative breast tumours and/or premenopausal breast cancer of different ethnicities.

Acknowledgements

This research was supported by a ‘VLIR Own Initiative Programme’ between Belgium and South Africa (ZEIN2011PR387), a grant of the South African Medical Research Council, a grant from CANSA (Cancer Association of South Africa) and partially funded by Stichting tegen Kanker (project 2012–198). The authors wish to thank Mrs. Marianne Gomes for providing genetic counselling to a number of patients in the study. Additionally the lab staffs at the Center for Medical Genetics, Ghent University Hospital, Belgium and the Division of Human Genetics, NHLS, and School of Pathology, University of the Witwatersrand, Johannesburg are acknowledged for their assistance. We are also grateful to Dr. Sarah Rayne for helping in collecting samples. We would like to thank all the patients who participated in this study.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Competing interests

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Authors’ contributions

Additional files

Additional file 1: Table S1. Overview of grading and staging of breast cancer on diagnosis (DOC 30 kb)

Additional file 2: Table S2. Overview of sequencing coverage per run (DOC 29 kb)

National cancer registry report. National Health laboratory Service. 2006;http://www.nioh.ac.za (http://www.nioh.ac.za/assets/files/NCR_2006_TABLES_FINAL.pdf).

Statistics South Africa. Mid-year population estimates. 2013. http://www.statssa.gov.za/publications/P0302/P03022013.pdf

Slattery ML, Kerber RA. A comprehensive evaluation of family history and breast-cancer risk - the Utah population database. Jama-J Am Med Assoc. 1993;270(13):1563–8.CrossRef

West DS, Greene PG, Kratt PP, Pulley L, Weiss HL, Siegfried N, et al. The impact of a family history of breast cancer on screening practices and attitudes in low-income, rural, African American women. J Womens Health. 2003;12(8):779–87.CrossRef

Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkas K, Roberts J, et al. Breast-cancer risk in families with mutations in PALB2. New England J Med. 2014;371(6):497–506.CrossRef

Oluwagbemiga LA, Oluwole A, Kayode AA. Seventeen years after BRCA1: what is the BRCA mutation status of the breast cancer patients in Africa? - a systematic review. SpringerPlus. 2012;1(1):83.CrossRefPubMedPubMedCentral

Reeves MD, Yawitch TM, van der Merwe NC, van den Berg HJ, Dreyer G, van Rensburg EJ. BRCA1 mutations in South African breast and/or ovarian cancer families: evidence of a novel founder mutation in Afrikaner families. Int J Cancer J Int Cancer. 2004;110(5):677–82.CrossRef

Sluiter M, Mew S, van Rensburg EJ. PALB2 sequence variants in young South African breast cancer patients. Familial Cancer. 2009;8(4):347–53.CrossRefPubMed

Sluiter MD, van Rensburg EJ. Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation. Breast Cancer Res Treat. 2011;125(2):325–49.CrossRefPubMed

10.

van der Merwe NC, Hamel N, Schneider SR, Apffelstaedt JP, Wijnen JT, Foulkes WD. A founder BRCA2 mutation in non-Afrikaner breast cancer patients of the Western Cape of South Africa. Clin Genet. 2012;81(2):179–84.CrossRefPubMed

11.

Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336(20):1401–8.CrossRefPubMed

12.

Schuster SC, Miller W, Ratan A, Tomsho LP, Giardine B, Kasson LR, et al. Complete Khoisan and Bantu genomes from southern Africa. Nature. 2010;463(7283):943–7.CrossRefPubMedPubMedCentral

13.

Schoeman M, Apffelstaedt JP, Baatjes K, Urban M. Implementation of a breast cancer genetic service in South Africa - lessons learned. South African Med J = Suid-Afrikaanse tydskrif vir geneeskunde. 2013;103(8):529–33.

14.

Edge J, Buccimazza I, Cubasch H, Panieri E. The Challenges of managing breast cancer in the developing world- a perspective from sub-Saharan Africa. S Afr Med J. 2014;104(5):377–9.CrossRefPubMed

15.

Walker AR, Adam FI, Walker BF. Breast cancer in black African women: a changing situation. J R Soc Promot Heal. 2004;124(2):81–5.CrossRef

16.

Dickens C, Duarte R, Zietsman A, Cubasch H, Kellett P, Schuz J, Kielkowski D, McCormack VA: Racial comparison of receptor-defined breast cancer in Southern African women: subtype prevalence and age-incidence analysis of nationwide cancer registry data. Cancer Epidemiol Biomarkers Prevent. 2014;23(11):2311-21.

17.

Herd O, Francies F, Cairns A, Muller X, Slabbert J, Baeyens A: Ethnical differences in breast cancer characteristics in South African population. Breast J 2015;21(4):447-9.

18.

Pollan M. Epidemiology of breast cancer in young women. Breast Cancer Res Treat. 2010;123 Suppl 1:3–6.CrossRefPubMed

19.

Krainer M, Silva-Arrieta S, FitzGerald MG, Shimada A, Ishioka C, Kanamaru R, et al. Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med. 1997;336(20):1416–21.CrossRefPubMed

20.

Langston AA, Malone KE, Thompson JD, Daling JR, Ostrander EA. BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med. 1996;334(3):137–42.CrossRefPubMed

21.

Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999;91(11):943–9.CrossRefPubMed

22.

Pal T, Bonner D, Cragun D, Johnson S, Akbari M, Servais L, et al. BRCA sequencing and large rearrangement testing in young Black women with breast cancer. J Commun Genet. 2014;5(2):157–65.CrossRef

23.

Kruger W, Apffelstaedt J. Young breast cancer patients in the developing world: incidence, choice of surgical treatment and genetic factors. South African Family Practice. 2007;49(9):18–24.CrossRef

24.

Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–48.CrossRefPubMed

25.

McCormack VA, Joffe M, van den Berg E, Broeze N, Silva Idos S, Romieu I, et al. Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series. Breast Cancer Res BCR. 2013;15(5):R84.CrossRefPubMed

26.

Robertson L, Hanson H, Seal S, Warren-Perry M, Hughes D, Howell I, et al. BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. British J Cancer. 2012;106(6):1234–8.CrossRef

27.

Young SR, Pilarski RT, Donenberg T, Shapiro C, Hammond LS, Miller J, et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer. 2009;9:86.CrossRefPubMedPubMedCentral

28.

De Leeneer K, Hellemans J, Steyaert W, Lefever S, Vereecke I, Debals E, Crombez B, Baetens M, Van Heetvelde M, Coppieters F et al: Flexible, Scalable and Efficient Targeted Resequencing on a Benchtop Sequencer for Variant Detection in Clinical Practice. Human Mutation. 2015;36(3):379-87.

29.

Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215.CrossRefPubMedPubMedCentral

30.

van den Ouweland AM, Dinjens WN, Dorssers LC, van Veghel-Plandsoen MM, Bruggenwirth HT, Withagen-Hermans CJ, et al. Deletion of exons 1a-2 of BRCA1: a rather frequent pathogenic abnormality. Genetic Testing Mol Biomark. 2009;13(3):399–406.CrossRef

31.

Ameziane N, van den Ouweland AM, Adank MA, Vijzelaar RN, Errami A, Dorsman JC, et al. Lack of large genomic deletions in BRIP1, PALB2, and FANCD2 genes in BRCA1/2 negative familial breast cancer. Breast Cancer Res Treat. 2009;118(3):651–3.CrossRefPubMed

32.

Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95(19):1482–5.CrossRefPubMed

33.

Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008;26(26):4282–8.CrossRefPubMed

34.

Hartman AR, Kaldate RR, Sailer LM, Painter L, Grier CE, Endsley RR, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 2012;118(11):2787–95.CrossRefPubMed

35.

Malone KE, Daling JR, Doody DR, Hsu L, Bernstein L, Coates RJ, et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res. 2006;66(16):8297–308.CrossRefPubMed

36.

Pal T, Bonner D, Kim J, Monteiro AN, Kessler L, Royer R, et al. Early onset breast cancer in a registry-based sample of African-american women: BRCA mutation prevalence, and other personal and system-level clinical characteristics. Breast J. 2013;19(2):189–92.CrossRefPubMed

37.

Schmidt MK, Tollenaar RA, de Kemp SR, Broeks A, Cornelisse CJ, Smit VT, et al. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol. 2007;25(1):64–9.CrossRefPubMed

38.

Bell DW, Kim SH, Godwin AK, Schiripo TA, Harris PL, Haserlat SM, et al. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer J Int Cancer. 2007;121(12):2661–7.CrossRef

39.

Adank MA, Jonker MA, Kluijt I, van Mil SE, Oldenburg RA, Mooi WJ, et al. CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women. J Med Genet. 2011;48(12):860–3.CrossRefPubMed

40.

Churpek JE, Walsh T, Zheng Y, Moton Z, Thornton AM, Lee MK, et al. Inherited predisposition to breast cancer among African American women. Breast Cancer Res Treatment. 2015;149(1):31–9.CrossRef

41.

Salas A, Carracedo A, Richards M, Macaulay V. Charting the ancestry of African Americans. Am J Human Genet. 2005;77(4):676–80.CrossRef

42.

Zhang J, Fackenthal JD, Huo D, Zheng Y, Olopade OI. Searching for large genomic rearrangements of the BRCA1 gene in a Nigerian population. Breast Cancer Res Treatment. 2010;124(2):573–7.CrossRef

43.

Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008;29(11):1282–91.CrossRefPubMedPubMedCentral

44.

Spearman AD, Sweet K, Zhou XP, McLennan J, Couch FJ, Toland AE. Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance. J Clin Oncol. 2008;26(33):5393–400.CrossRefPubMedPubMedCentral

45.

Millot GA, Carvalho MA, Caputo SM, Vreeswijk MP, Brown MA, Webb M, et al. A guide for functional analysis of BRCA1 variants of uncertain significance. Hum Mutat. 2012;33(11):1526–37.CrossRefPubMedPubMedCentral

46.

Moghadasi S, Hofland N, Wouts JN, Hogervorst FB, Wijnen JT, Vreeswijk MP, et al. Variants of uncertain significance in BRCA1 and BRCA2 assessment of in silico analysis and a proposal for communication in genetic counselling. J Med Genet. 2013;50(2):74–9.CrossRefPubMed

47.

Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F, et al. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. Jama. 2005;294(15):1925–33.CrossRefPubMed

48.

Zhang F, Fan Q, Ren K, Andreassen PR. PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. Mol Cancer Res MCR. 2009;7(7):1110–8.CrossRefPubMed

49.

Park JY, Singh TR, Nassar N, Zhang F, Freund M, Hanenberg H, et al. Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair. Oncogene. 2014;33(40):4803–12.CrossRefPubMed

50.

Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. Jama-J Am Med Assoc. 2006;295(12):1379–88.CrossRef

51.

Yawitch TM, Van Rensburg EJ, Mertz M, Falkson CI. Absence of commonly recurring BRCA1 mutations in black South African women with breast cancer. South African Med J Suid-Afrikaanse Tydskrif vir Geneeskunde. 2000;90(8):788.

52.

Schlebusch CM, Dreyer G, Sluiter MD, Yawitch TM, Van Den Berg HJ, Van Rensburg EJ. Cancer prevalence in 129 breast-ovarian cancer families tested for BRCA1 and BRCA2 mutations. South African Med J = Suid-Afrikaanse Tydskrif vir Geneeskunde. 2010;100(2):113–7.

53.

Wong-Brown MW, Meldrum CJ, Carpenter JE, Clarke CL, Narod SA, Jakubowska A, Rudnicka H, Lubinski J, Scott RJ: Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2015;150(1):71-80.

54.

Colombo M, De Vecchi G, Caleca L, Foglia C, Ripamonti CB, Ficarazzi F, et al. Comparative in vitro and in silico analyses of variants in splicing regions of BRCA1 and BRCA2 genes and characterization of novel pathogenic mutations. PLoS One. 2013;8(2):e57173.CrossRefPubMedPubMedCentral

55.

Kim H, Cho DY, Choi DH, Choi SY, Shin I, Park W, et al. Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3,922 Korean patients with breast and ovarian cancer. Breast Cancer Res Treat. 2012;134(3):1315–26.CrossRefPubMed

56.

Novakovic S, Milatovic M, Cerkovnik P, Stegel V, Krajc M, Hocevar M, et al. Novel BRCA1 and BRCA2 pathogenic mutations in Slovene hereditary breast and ovarian cancer families. Int J Oncol. 2012;41(5):1619–27.PubMedPubMedCentral

57.

Saxena S, Chakraborty A, Kaushal M, Kotwal S, Bhatanager D, Mohil RS, et al. Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India. BMC Med Genet. 2006;7:75.CrossRefPubMedPubMedCentral

58.

Judkins T, Hendrickson BC, Deffenbaugh AM, Eliason K, Leclair B, Norton MJ, et al. Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations. Cancer Res. 2005;65(21):10096–103.CrossRefPubMed

59.

Borg A, Haile RW, Malone KE, Capanu M, Diep A, Torngren T, et al. Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study. Hum Mutat. 2010;31(3):E1200–40.CrossRefPubMedPubMedCentral

60.

McKean-Cowdin R, Spencer Feigelson H, Xia LY, Pearce CL, Thomas DC, Stram DO, et al. BRCA1 variants in a family study of African-American and Latina women. Hum Genet. 2005;116(6):497–506.CrossRefPubMed

61.

Hu N, Wang C, Han XY, He LJ, Tang ZZ, Giffen C, et al. Evaluation of BRCA2 in the genetic susceptibility of familial esophageal cancer. Oncogene. 2004;23(3):852–8.CrossRefPubMed

62.

Haffty BG, Choi DH, Goyal S, Silber A, Ranieri K, Matloff E, et al. Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups. Ann Oncol. 2009;20(10):1653–9.CrossRefPubMed

63.

Esashi F, Christ N, Gannon J, Liu Y, Hunt T, Jasin M, et al. CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. Nature. 2005;434(7033):598–604.CrossRefPubMed

Titel: BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer
verfasst von: F. Z. Francies
T. Wainstein
K. De Leeneer
A. Cairns
M. Murdoch
S. Nietz
H. Cubasch
B. Poppe
T. Van Maerken
B. Crombez
I. Coene
R. Kerr
J. P. Slabbert
A. Vral
A. Krause
A. Baeyens
K. B. M. Claes
Publikationsdatum: 01.12.2015
Verlag: BioMed Central
Erschienen in: BMC Cancer / Ausgabe 1/2015
Elektronische ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-015-1913-6

Neu im Fachgebiet Onkologie

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Brustkrebs-Prävention wird neu gedacht

04.06.2024 ASCO 2024 Kongressbericht

Zurzeit untersuchen Forschende verschiedene neue Ansätze zur Prävention von Brustkrebs bei Personen mit hohem Risiko. Darunter Denosumab, die prophylaktische Bestrahlung der Brust – und Impfungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Electronic supplementary material

Competing interests

Authors’ contributions

Background

Methods

Patients

DNA extraction

Target enrichment, library preparation and sequencing

Sanger sequencing

MLPA

Data analysis

Statistical analysis

Results

Discussion

Conclusion

Acknowledgements

Competing interests

Authors’ contributions

Additional files

Weitere Artikel der Ausgabe 1/2015

Small nucleolar RNA U91 is a new internal control for accurate microRNAs quantification in pancreatic cancer

Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC)

Clinicopathological and prognostic significance of FOXP3+ tumor infiltrating lymphocytes in patients with breast cancer: a meta-analysis

Sex differences in cancer survival in Estonia: a population-based study

Serine threonine tyrosine kinase 1 is a potential prognostic marker in colorectal cancer

Lung cancer mortality and years of potential life lost among males and females over six decades in a country with high smoking prevalence: an observational study

Neu im Fachgebiet Onkologie

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

Brustkrebs-Prävention wird neu gedacht

Update Onkologie